Phase III Hallmark DUAL: ASV+DCV (Nulls/Partials, Intolerants/Ineligibles. Naives)
Status:
Completed
Trial end date:
2014-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to estimate efficacy, as determined by the proportion of
subjects with Sustained virologic response at post-treatment Week 12 (SVR12), defined as
Hepatitis C virus (HCV) Ribonucleic acid (RNA) < Limit of quantitation (LOQ) at
post-treatment Week 12, for subjects who are prior null or partial responders to P/R or who
are treatment-naive.